Organon & Co. Stock Plummets to New 52-Week Low of $6.18

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.18 on October 30, 2025. This significant decline reflects a challenging year for the company, with its stock price plummeting by 68.28% over the past year, starkly contrasting with the S&P 500's performance, which has seen an increase of 18.13% during the same period.
The company's market capitalization stands at USD 2,722 million, and it currently has a price-to-earnings (P/E) ratio of 3.00, indicating a low valuation compared to its earnings. Additionally, Organon & Co. has a dividend yield of 0.38% and a debt-to-equity ratio of 11.32, suggesting a relatively low level of debt. However, the return on equity is notably high at 111.78%, which may indicate effective management of shareholder equity.

Despite these metrics, the company has faced challenges, including a significant drop in net profit and an increase in raw material costs. The inventory turnover ratio has also reached a low of 2 times, further highlighting operational difficulties. Overall, Organon & Co.'s recent performance underscores a period of notable volatility and underperformance in the market.